Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy
Molecular Therapy · 2023
DOI: 10.1016/j.ymthe.2023.03.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2023. Verfasst von Grant J Logan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hos…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Capsid. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health, National Health and Medical Research Council.
Abstract (Originalsprache)
Success in the treatment of infants with spinal muscular atrophy (SMA) underscores the potential of vectors based on adeno-associated virus (AAV). However, a major obstacle to the full realization of this potential is pre-existing natural and therapy-induced anti-capsid humoral immunity. Structure-guided capsid engineering is one possible approach to surmounting this challenge but necessitates an understanding of capsid-antibody interactions at high molecular resolution. Currently, only mouse-derived monoclonal antibodies (mAbs) are available to structurally map these interactions, which presupposes that mouse and human-derived antibodies are functionally equivalent. In this study, we have characterized the polyclonal antibody responses of infants following AAV9-mediated gene therapy for SMA and recovered 35 anti-capsid mAbs from the abundance of switched-memory B (smB) cells present in these infants. For 21 of these mAbs, seven from each of three infants, we have undertaken functional and structural analysis measuring neutralization, affinities, and binding patterns by cryoelectron microscopy (cryo-EM). Four distinct patterns were observed akin to those reported for mouse-derived mAbs, but with early evidence of differing binding pattern preference and underlying molecular interactions. This is the first human and largest series of anti-capsid mAbs to have been comprehensively characterized and will prove to be powerful tools for basic discovery and applied purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hospitals Network, Westmead, NSW, Australia.
- Department of Biochemistry and Molecular Biology, Center for Structural Biology, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA.
- School of Women's and Children's Health, University of New South Wales Medicine, UNSW Sydney, Sydney, NSW, Australia.
- Garvan Institute of Medical Research, UNSW Sydney, Faculty of Medicine, Darlinghurst, NSW, Australia.
- Garvan Institute of Medical Research, UNSW Sydney, Faculty of Medicine, Darlinghurst, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, NSW, Australia.
- Westmead Institute for Medical Research, Centre for Immunology and Allergy Research, Westmead, NSW, Australia.
Förderung
- NIGMS NIH HHS
- National Institutes of Health
- National Health and Medical Research Council
- Rebecca L Cooper Medical Research Foundation
Zitieren
APA
Logan, G. J., Mietzsch, M., Khandekar, N., D'Silva, A., Anderson, D., Mandwie, M., Hsi, J., Nelson, A. R., Chipman, P., Jackson, J., Schofield, P., Christ, D., Goodnow, C. C., Reed, J. H., Farrar, M. A., McKenna, R., & Alexander, I. E. (2023). Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.03.032
Vancouver
Logan GJ, Mietzsch M, Khandekar N, D'Silva A, Anderson D, Mandwie M, et al. Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy. Molecular Therapy. 2023. doi:10.1016/j.ymthe.2023.03.032
BibTeX
@article{Logan2023,
author = {Logan, Grant J and Mietzsch, Mario and Khandekar, Neeta and D'Silva, Arlene and Anderson, Daniel and Mandwie, Mawj and Hsi, Jane and Nelson, Austin R and Chipman, Paul and Jackson, Jennifer and Schofield, Peter and Christ, Daniel and Goodnow, Christopher C and Reed, Joanne H and Farrar, Michelle A and McKenna, Robert and Alexander, Ian E},
title = {Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy},
journal = {Molecular Therapy},
year = {2023},
doi = {10.1016/j.ymthe.2023.03.032}
}
EUVIMED